NOVAVAX Inc.

Nov 20, 09
	NEW STORY
09:35 ET	Novavax Prices Public Offering of Common Stock
	NEW STORY
07:45 ET	Novavax Announces Public Offering of Common Stock
Nov 16, 09
08:00 ET	NOVAVAX Completes First Stage of Enrollment in Pivotal H1N1 Influenza Vaccine Study in the Country of Mexico
Nov 11, 09
10:30 ET	NOVAVAX to Present at the Influenza Congress USA 2009
Nov 10, 09
08:00 ET	Novavax Begins Phase IIa Study of Seasonal Influenza Vaccine in Older Adults
Nov 06, 09
08:00 ET	Novavax Reports Third Quarter 2009 Financial Results
Nov 02, 09
08:00 ET	Novavax Reports Positive Data for its Trivalent Seasonal Influenza (VLP) Vaccine Candidate in a Second Phase II Study
Oct 30, 09
12:33 ET	Novavax Announces Release Date of 2009 Third Quarter Financial Results and Investor Conference Call
Oct 29, 09
12:05 ET	NOVAVAX to Present at Oppenheimer 20th Annual Healthcare Conference
08:04 ET	Novavax Announces Poster Presentation at the 47th Annual Meeting of the IDSA
Oct 28, 09
08:04 ET	Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India
Oct 23, 09
10:00 ET	Novavax to Present at 8th Annual BIO Investor Forum 2009
Oct 21, 09
07:30 ET	Novavax and Xcellerex Announce Collaboration to Develop Large-scale Manufacturing Process for 2009 H1N1 Influenza VLP Vaccine
Oct 20, 09
04:30 ET	Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico
Oct 13, 09
08:30 ET	Novavax Awarded NIH Grant for Respiratory Syncytial Virus (RSV) Vaccine Program
Oct 06, 09
10:14 ET	Novavax CEO to Present at the World Vaccine Congress 2009, Lyon, France
Oct 01, 09
16:05 ET	Novavax Announces Board of Director Changes
Sep 01, 09
08:00 ET	NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate
Aug 18, 09
08:00 ET	NOVAVAX Virus-Like Particle Vaccine Protects Against 2009 Pandemic H1N1 Influenza Virus
Aug 07, 09
08:30 ET	Novavax Reports Second Quarter 2009 Financial Results
Aug 06, 09
16:48 ET	Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer
Aug 05, 09
07:30 ET	NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone
Jul 31, 09
11:00 ET	Novavax Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call
Jul 22, 09
08:00 ET	Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
Jul 21, 09
15:00 ET	Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances
Jul 15, 09
12:30 ET	Novavax Announces Repayment of $5 Million of Convertible Debt
Jul 09, 09
08:00 ET	Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
Jun 30, 09
11:38 ET	Spanish Government Selects Novavax's VLP Technology for Comprehensive Flu Vaccine Solution in Spain
Jun 26, 09
08:30 ET	Novavax Appoints Stanley Erck to Board of Directors
Jun 24, 09
10:00 ET	Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
Jun 18, 09
14:00 ET	Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009
Jun 04, 09
08:00 ET	Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
May 15, 09
08:40 ET	Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
May 08, 09
08:00 ET	Novavax Reports First Quarter 2009 Financial Results
May 05, 09
09:30 ET	Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
May 04, 09
16:04 ET	Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
Apr 29, 09
09:27 ET	Novavax Announces Early Retirement of $17 Million of Convertible Debt
Apr 14, 09
08:00 ET	NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
Apr 01, 09
15:56 ET	Novavax Announces Closing of $11 Million Common Stock Sale to Subsidiary of Cadila Pharmaceuticals
Mar 31, 09
15:08 ET	Novavax Reports Fourth Quarter and 2008 Year-End Financial Results
15:00 ET	Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
Mar 26, 09
09:27 ET	Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
Mar 17, 09
08:00 ET	Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
Mar 13, 09
14:18 ET	Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
Feb 27, 09
08:00 ET	NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine Candidate Directed Against the Fusion (F) Protein
Feb 19, 09
09:36 ET	Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate
Feb 17, 09
08:30 ET	Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference
Feb 04, 09
08:00 ET	Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
Jan 26, 09
11:07 ET	Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
Jan 23, 09
10:20 ET	Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009
Dec 11, 08
08:00 ET	Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate
Dec 09, 08
12:00 ET	NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine Candidate
Dec 08, 08
08:48 ET	Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
08:00 ET	Novavax Announces Preclinical Data for Respiratory Syncytial Virus Vaccine Candidate
Dec 01, 08
08:45 ET	Novavax CEO to Present at Piper Jaffray 20th Annual Healthcare Conference
Nov 13, 08
12:55 ET	Cleveland Clinic Recognizes New Strategies for Creating Vaccines for Avian Flu as a Top Ten Medical Innovation for 2009
Nov 12, 08
08:30 ET	Novavax CEO to Present at Lazard Capital Markets 5th Annual Healthcare Conference
Nov 10, 08
08:00 ET	Novavax Reports Third Quarter 2008 Financial Results
Nov 04, 08
08:00 ET	Novavax Announces Release Date of 2008 Third Quarter Financial Results and Investor Conference Call
Oct 29, 08
13:48 ET	Novavax CEO to Present at Oppenheimer 19th Annual Healthcare Conference
Oct 28, 08
14:54 ET	Novavax CEO to Present at BIO Investor Forum 2008
Sep 29, 08
12:45 ET	NOVAVAX Featured at Clinton Global Initiative 2008 Annual Meeting
Sep 19, 08
10:33 ET	NOVAVAX CEO to Present at 2008 UBS Global Life Sciences Conference
08:00 ET	Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
Sep 16, 08
08:22 ET	Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
Aug 26, 08
08:00 ET	Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
Aug 21, 08
08:00 ET	Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008
Aug 08, 08
08:00 ET	Novavax Reports Second Quarter 2008 Financial Results
Aug 04, 08
11:43 ET	Novavax CEO to Present at BMO Capital Markets Focus on Healthcare Conference
08:37 ET	Novavax Announces Release Date of 2008 Second Quarter Financial Results and Investor Conference Call
Aug 01, 08
11:45 ET	Novavax Announces Closing of $18 Million Registered Direct Offering
Jul 29, 08
09:27 ET	Novavax Announces Pricing of $18 Million Financing of Common Stock and Warrants
Jun 26, 08
10:00 ET	Novavax to Join Russell 3000 Index
Jun 16, 08
11:42 ET	Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
May 28, 08
12:30 ET	Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
May 22, 08
08:30 ET	Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
May 15, 08
08:00 ET	Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
May 14, 08
08:30 ET	Novavax CEO to Present at ACUMENBioFin's 5th Annual Global Healthcare Conference
May 09, 08
08:00 ET	Novavax Reports First Quarter 2008 Financial Results
May 06, 08
09:15 ET	Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
May 01, 08
08:00 ET	Novavax Opens Its First U.S. Vaccine Plant
Apr 21, 08
11:00 ET	Novavax CEO to Present at the World Vaccine Congress 2008
Apr 16, 08
08:30 ET	Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
Mar 14, 08
08:00 ET	Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
Mar 07, 08
08:30 ET	Novavax CEO to Present at the Partnering for Global Health Forum
08:00 ET	Novavax Announces Release Date of 2007 Fourth Quarter, Full Year Financial Results and Investor Conference Call
Feb 27, 08
15:00 ET	Novavax CEO to Present at Susquehanna's Second SIGnificant Options in Healthcare Conference
Feb 19, 08
11:18 ET	Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
Feb 06, 08
16:00 ET	Novavax CEO to Present at BIO CEO & Investor Conference
Dec 20, 07
07:30 ET	Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
Dec 17, 07
07:30 ET	Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program
Dec 10, 07
07:42 ET	GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
Nov 30, 07
10:30 ET	Novavax CEO to Present at BMO Capital Markets: Focus on Healthcare Conference
Nov 12, 07
07:30 ET	Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs
Nov 02, 07
16:00 ET	Novavax Announces Release Date of 2007 Third Quarter Financial Results and Investor Conference Call
Oct 29, 07
08:30 ET	Novavax CEO to Present at ACUMENBioFin's 9th Annual Healthcare Conference
Oct 25, 07
10:00 ET	Novavax and Allergan Terminate Manufacturing Supply Agreement for Estrasorb
Sep 14, 07
10:30 ET	Novavax CEO to Present at the 2007 UBS Global Life Sciences Conference
Sep 12, 07
08:00 ET	Novavax Announces New Discovery Program for Varicella Zoster Virus Vaccine
Aug 22, 07
14:30 ET	Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
Aug 15, 07
08:30 ET	Novavax Announces Publication of HIV/AIDS Vaccine Research in Journal of Virology
Aug 10, 07
07:30 ET	Novavax Reports Second Quarter 2007 Financial Results
Aug 03, 07
08:30 ET	Novavax Announces Release Date of 2007 Second Quarter Financial Results and Investor Conference Call
Jul 31, 07
10:18 ET	Novavax Begins Human Clinical Testing of Novel Pandemic Flu Vaccine
Jul 09, 07
08:00 ET	Novavax Licenses Wyeth's Virus-Like Particle Technology
Jul 05, 07
16:15 ET	Novavax Names Len Stigliano Chief Financial Officer
Jun 21, 07
08:30 ET	Novavax Executive Receives CDC Science Award
Jun 18, 07
08:15 ET	Novavax Announces Restructuring of Existing Convertible Debt
Jun 14, 07
08:30 ET	Novavax CEO to Present at Piper Jaffray London Health Care Conference
Jun 08, 07
09:00 ET	Novavax CEO to Present at Needham's 6th Annual Biotechnology & Medical Technology Conference
Jun 01, 07
08:30 ET	Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal Challenge of Live Virus, Pre-Clinical Data Show
May 22, 07
08:30 ET	Novavax CEO to Present at Friedman, Billings, Ramsey & Co.'s 2007 Growth Conference
May 11, 07
07:00 ET	Novavax Reports First Quarter 2007 Financial Results
May 04, 07
08:30 ET	Novavax CEO to Present at ACUMENBioFin's 4th Annual Global Healthcare Conference
May 03, 07
08:30 ET	Novavax Reports Positive Pre-Clinical Study Results from Live Virus Challenge to Pandemic Flu Vaccine
May 01, 07
16:00 ET	Novavax Announces Release Date of 2007 First Quarter Financial Results and Investor Conference Call
Apr 05, 07
18:00 ET	Novavax Appoints Interim CFO
Apr 02, 07
08:51 ET	Novavax Vaccine Provides Robust Immune Response, Pre-Clinical Data Show
Mar 14, 07
08:30 ET	Novavax Appoints James Robinson Vice President of Technical and Quality Operations
07:00 ET	Novavax Reports Fourth Quarter and 2006 Year-End Financial Results
Mar 08, 07
08:30 ET	Novavax Board of Directors Elect John Lambert as Executive Chairman
Mar 06, 07
08:30 ET	Novavax Announces Release Date of 2006 Fourth Quarter, Full Year Financial Results and Investor Conference Call
Mar 02, 07
09:14 ET	Novavax Licenses New VLP Technology From University of Massachusetts Medical School
Feb 21, 07
08:30 ET	Pre-Clinical Study of Novavax's Seasonal Influenza Vaccine Published in Journal 'Vaccine'
Feb 07, 07
08:30 ET	Novavax CEO to Present at BIO CEO & Investor Conference
Jan 23, 07
08:30 ET	Novavax's Dr. Gale Smith to Chair Scientific Congress
Jan 22, 07
16:25 ET	New Data Support Novavax's Pandemic Flu Vaccines
Jan 17, 07
16:30 ET	Novavax to Participate in Phacilitate Vaccine Forum
Jan 16, 07
11:42 ET	Novavax and Collaborators Significantly Improve VLP Vaccine for HIV/AIDS
Dec 13, 06
08:33 ET	Novavax Relocating Corporate Headquarters to Maryland
Dec 05, 06
08:00 ET	Novavax CEO to Present at BMO Nesbitt Burns Healthcare Conference
Nov 22, 06
08:36 ET	Novavax Files $100 Million Shelf Registration Statement
Nov 14, 06
08:00 ET	Novavax Reports Third Quarter 2006 Financial Results
Nov 08, 06
07:00 ET	Novavax's Pandemic Influenza Vaccine Candidates Trigger Robust Immune Response In Pre-Clinical Models
Nov 07, 06
20:56 ET	Novavax Announces Release Date of Third Quarter 2006 Financial Results and Investor Conference Call
Nov 01, 06
07:50 ET	Novavax CEO to Present at Rodman & Renshaw's Annual Healthcare Conference
Oct 31, 06
07:00 ET	CDC TO EVALUATE NOVAVAX'S PANDEMIC INFLUENZA VACCINE CANDIDATE
Oct 10, 06
08:16 ET	Novavax Details Advantages of Portable Manufacturing Process at World Vaccine Congress
Oct 02, 06
07:00 ET	Novavax Names Dr. Penny Heaton Chief Medical Officer
Sep 21, 06
07:00 ET	Novavax CEO to Present at UBS Global Life Sciences Conference
Sep 19, 06
07:00 ET	Novavax Initiates Pre-Clinical Testing of Intranasal Influenza Vaccine
Sep 06, 06
07:30 ET	Novavax Elects Dr. Tom Monath to Board of Directors
Aug 17, 06
09:24 ET	Novavax Names Jeffrey Church Chief Financial Officer
Aug 14, 06
08:52 ET	Novavax Announces Second Quarter Financial Results
Aug 02, 06
11:30 ET	Novavax Announces Release Date of Second Quarter 2006 Financial Results and Investor Conference Call
Jul 31, 06
09:38 ET	Novavax Succeeds in Making Vaccine to Protect Against New Mutation of Avian Influenza
Jul 18, 06
09:03 ET	Novavax Receives Positive Results From Pre-Clinical Studies of Influenza Vaccines
Jul 12, 06
16:25 ET	Novavax Board Appoints Current Director to Audit Committee
Jun 12, 06
09:23 ET	Novavax Names Mariann Caprino Vice President of Corporate Communications and Investor Relations
Jun 08, 06
07:00 ET	Novavax Names Executive Director of Biologic Product Discovery
May 24, 06
10:19 ET	Novavax Added to NASDAQ Biotech Index
May 19, 06
06:00 ET	Novavax and Esprit Pharma to Co-develop Novel Medicine for Female Sexual Desire Disorder
May 15, 06
07:00 ET	Novavax Announces First Quarter 2006 Financial Results
May 11, 06
10:47 ET	Novavax Strengthens Vaccine Development Team with Two New Appointments
May 10, 06
07:00 ET	Novavax Head of Pharmaceutical Development to Present on Micellar Nanoparticle Technology at Particles 2006 Meeting
May 09, 06
07:00 ET	Novavax to Present at the Rodman & Renshaw 3rd Annual Global Healthcare Conference
May 05, 06
14:46 ET	Novavax Announces Release Date of First Quarter 2006 Financial Results and Investor Conference Call
May 01, 06
09:27 ET	Novavax's Head Of Vaccine Research To Participate In WHO Meeting To Develop Global Action Plan For Pandemic Influenza
Apr 28, 06
09:47 ET	Novavax Board Elects Dr. James B. Tananbaum as Director
Apr 20, 06
07:00 ET	Novavax to Present at UBS Global Specialty Pharmaceuticals Conference
Apr 17, 06
07:00 ET	Novavax Successfully Completes Additional Vaccine Milestone
Apr 10, 06
17:18 ET	Novavax to Present at BIO 2006 Chicago Annual International Convention
Mar 31, 06
07:00 ET	Novavax Bond Holders Elect to Convert $7.0 Million of Outstanding Notes
Mar 21, 06
07:50 ET	Novavax Executes Definitive Agreement for $38 Million Public Offering
Mar 20, 06
07:02 ET	Novavax CEO to Present at World Vaccine Congress 2006
Mar 16, 06
09:11 ET	Novavax Receives Additional Government Funding for HIV/AIDS Vaccine Research
09:03 ET	Novavax Receives Additional Government Funding for HIV/AIDS Vaccine Research
07:02 ET	Novavax Receives Additional Government Funding for IV/AIDS Vaccine Research
Mar 09, 06
18:45 ET	U.S. Senator Rick Santorum (R-PA) Will Tour Novavax Facility
Mar 06, 06
07:01 ET	Novavax and Bharat Biotech Announce Strategic Alliance for Pandemic Influenza Vaccine Development
Mar 01, 06
08:04 ET	Novavax Announces Fourth Quarter and Year-End 2005 Financial Results
Feb 28, 06
08:46 ET	Novavax Announces Strategic Alliance With PacificGMP on Pandemic Influenza Vaccine Production Technologies
Feb 27, 06
08:29 ET	Novavax Announces $20 Million Common Stock Offering to Kleiner Perkins Caufield & Byers and Prospect Venture Partners
Feb 21, 06
16:08 ET	Novavax Announces Release Date of Fourth Quarter and Year-End 2005 Financial Results and Investor Conference Call
Feb 15, 06
08:40 ET	Novavax Announces Research Collaboration With the University of Pittsburgh School of Medicine
Feb 14, 06
07:02 ET	Novavax to Present at BIO CEO & Investor Conference
Feb 02, 06
08:09 ET	Novavax Appoints New Vice President of Vaccine Research
Jan 10, 06
16:01 ET	Novavax to Present at the University of Maryland 'Avian Flu: What Can We Do?' Symposium
Dec 23, 05
07:00 ET	Novavax Receives $8.0 Million Cash Payment on ESTRASORB(R)
Dec 22, 05
07:00 ET	Novavax Files $100 Million Shelf Registration Statement
Nov 08, 05
07:36 ET	Novavax Announces Third Quarter 2005 Financial Results
Nov 04, 05
19:26 ET	Novavax to Present at Rodman & Renshaw Techvest 7th Annual Healthcare Conference
10:07 ET	Novavax Announces Release Date of Third Quarter 2005 Financial Results
Nov 02, 05
07:03 ET	Novavax Executes Definitive Agreements for $18 Million Public Offering
Oct 27, 05
08:13 ET	Novavax Bond Holders Elect to Convert $6 Million of Outstanding Notes
Oct 24, 05
17:04 ET	Novavax to Present at the C.E. Unterberg, Towbin Life Sciences Conference
Oct 18, 05
18:01 ET	Novavax Announces Conference Call
17:31 ET	Novavax Completes ESTRASORB Partnership
Oct 13, 05
08:01 ET	Novavax to Present at the 2005 Bio InvestorForum
Sep 23, 05
08:00 ET	Novavax Closes Sale of Non-Core Product Assets
Sep 13, 05
08:03 ET	Novavax Announces Strategic Alliance on Pandemic Influenza Vaccine Production Technologies
Sep 08, 05
08:03 ET	Novavax Appoints New Vice President of Pharmaceutical Development
Aug 25, 05
07:00 ET	Novavax reports positive preclinical results on its novel vaccine for pandemic influenza
Aug 09, 05
07:04 ET	Novavax announces second quarter results
06:55 ET	Novavax Announces New President, CEO and Board Member
Aug 03, 05
14:41 ET	Novavax announces release date of second quarter financial results
Jun 21, 05
15:53 ET	Novavax to present at BIO 2005 Forum
Jun 08, 05
08:18 ET	Novavax expands pipeline with pre-clinical results for two new compounds
May 24, 05
08:01 ET	Novavax Announces Positive Pre-Clinical Results
May 18, 05
09:45 ET	Novavax to present at the UBS Global Pharmaceuticals Conference
May 10, 05
07:03 ET	Novavax announces first quarter results
May 09, 05
09:03 ET	Novavax announces agreement to reduce ESTRASORB manufacturing costs
May 03, 05
09:27 ET	Novavax announces release date of first quarter results
Apr 14, 05
08:42 ET	Novavax to present at the World Vaccine Congress 2005
Apr 04, 05
08:04 ET	Novavax Announces Alternate Slate of Directors Has Been Rescinded
08:04 ET	Novavax Board of Directors Elects Gary C. Evans Chairman and Promotes Rahul Singhvi to Senior Vice-President and Chief Operating Officer
Mar 31, 05
11:32 ET	Novavax to present at the Stephens Nanotechnology conference
Mar 21, 05
17:13 ET	Novavax moves ahead with cost rationalization plan
Mar 16, 05
09:00 ET	Novavax partners with Ranbaxy to evaluate micellar nanoparticle technology applications
Mar 14, 05
18:30 ET	Novavax announces fourth quarter and fiscal 2004 results
Mar 01, 05
16:15 ET	Novavax Announces Release Date of Fourth Quarter and 2004 Year End Financial Results
Feb 04, 05
10:02 ET	Novavax Receives SARS Vaccine Funding From NIH
Jan 12, 05
17:51 ET	Novavax Updates 2005 First Half Milestones
Jan 10, 05
14:31 ET	Novavax's ESTRASORB Product Referenced on NBC's 'Today Show'
Dec 06, 04
08:31 ET	Novavax Updates Clinical Strategy for Testosterone Therapy ANDROSORB
Nov 01, 04
09:04 ET	Reminder: Novavax, Inc. to Report Third Quarter 2004 Results on November 3, 2004 and Host November 4 Webcast to Provide Update on Drug Delivery Product Development and Vaccine Pipeline
Oct 28, 04
16:07 ET	Novavax Appoints Susan B. Bayh to Board of Directors
Oct 26, 04
17:14 ET	Novavax Names Dr. Stephen I. Bandak, MB BS MRCP, Vice President of Medical Affairs
13:51 ET	Novavax, Inc. to Present at C.E. Unterberg Towbin Specialty Pharmaceutical Conference
Oct 21, 04
08:43 ET	Novavax, Inc. Hosts Conference Call to Provide Corporate Update
Sep 27, 04
08:59 ET	Novavax, Inc. Completes Relocation of Corporate Headquarters to Malvern, Pennsylvania
Aug 18, 04
08:33 ET	Novavax, Inc. Clarifies Recent Form S-3 Registration Statement Filings and Provides Update on ESTRASORB Prescription Data
Aug 09, 04
16:28 ET	Novavax, Inc. Announces Second Quarter 2004 Results
Aug 06, 04
07:04 ET	Novavax, Inc. Announces Relocation of Corporate Headquarters
Jul 28, 04
09:04 ET	Novavax, Inc. to Present at Banc of America Securities Specialty Pharmaceutical Conference
Jul 26, 04
09:24 ET	NOVAVAX To Report Second Quarter 2004 Financial Results On Monday, August 9, 2004
Jul 19, 04
07:30 ET	Novavax to Reacquire All Rights to ESTRASORB(R) From King Pharmaceuticals
Jul 01, 04
17:37 ET	Novavax, Inc. Provides Update on HIV Vaccine Programs
Jun 22, 04
08:01 ET	Novavax Enters Final Phase of Its Commercial Launch of ESTRASORB(R)
May 21, 04
11:22 ET	Novavax, Inc. to Present at UBS Warburg Global Specialty Pharmaceuticals Conference
May 05, 04
16:45 ET	Novavax, Inc. Announces First Quarter 2004 Results
Apr 28, 04
11:22 ET	Novavax to Report First Quarter 2004 Financial Results on Wednesday, May 5, 2004
Apr 21, 04
08:44 ET	Novavax's Launch of ESTRASORB(R) Underway
Apr 19, 04
08:31 ET	Novavax Added to Merrill Lynch Nanotech Index
Apr 14, 04
11:14 ET	Novavax President and CEO Nelson M. Sims to Be Featured Guest on Biotech Today Radio Program
Apr 07, 04
08:30 ET	Novavax Appoints New Vice President of Pharmaceutical Development and Manufacturing Operations
Mar 10, 04
16:59 ET	Novavax, Inc. Announces Fourth Quarter and Year End 2003 Results
Mar 08, 04
08:11 ET	Novavax, Inc. Comments on Estrogen-Alone Arm of Women's Health Initiative Study
Feb 20, 04
12:07 ET	Novavax, Inc. to Present at BIO CEO and Investor Conference 2004
Feb 19, 04
12:27 ET	Novavax to Report Fourth Quarter 2003 Financial Results on Wednesday, March 10, 2004
Jan 13, 04
10:22 ET	Novavax, Inc. Appoints Raymond J. Hage, Jr. as Vice President, Marketing
08:32 ET	Novavax, Inc. Appoints Gale E. Smith, Ph.D. as Vice President, Vaccine Development
Nov 18, 03
09:56 ET	Novavax, Inc. Completes $27.7 Million Equity Offering
Nov 13, 03
08:35 ET	Novavax, Inc. Announces Pricing of Offering
Nov 12, 03
16:05 ET	Novavax, Inc. Announces Intent to Offer Shares of Common Stock
Nov 10, 03
17:04 ET	Novavax, Inc. Announces 2003 Third Quarter Results
Nov 03, 03
15:25 ET	Novavax to Report Third Quarter 2003 Financial Results on Monday, November 10, 2003
Oct 20, 03
08:30 ET	Novavax, Inc. Ranked 169th Fastest Growing Technology Company in North America On the 2003 Deloitte & Touche Technology Fast 500
Oct 15, 03
08:37 ET	Novavax, Inc. Strengthens Management Team With the Addition of Two Seasoned Sales and Marketing Executives
Oct 10, 03
07:01 ET	Novavax and King Pharmaceuticals Announce FDA Approval of Estrasorb(TM)
Oct 01, 03
08:29 ET	Novavax, Inc. Ranked 5th on the 2003 Deloitte & Touche Technology Fast 50 Growing Technology Companies for the Maryland Region
Sep 29, 03
08:31 ET	Novavax Selected by NIAID/NIH to Develop HIV Vaccine
Aug 15, 03
16:46 ET	Novavax, Inc. Files $50 Million Shelf Registration
Aug 12, 03
18:05 ET	Novavax, Inc. Announces 2003 Second Quarter Results
Aug 08, 03
06:00 ET	Novavax, Inc. Appoints Nelson M. Sims President and CEO; Past President of Eli Lilly Canada
Jul 29, 03
08:31 ET	Novavax to Report Second Quarter 2003 Financial Results on Wednesday, August 13, 2003
Jul 15, 03
07:02 ET	Novavax Presents Results on Its Development of Functional Virus-Like Particles As Vaccines for Influenza at American Society of Virology 22nd Annual Meeting
Jun 26, 03
06:45 ET	Novavax, Inc. Announces Extension of FDA Review Time for Estrasorb(TM)
May 29, 03
13:39 ET	Novavax, Inc. to Present at UBS Warburg Global Specialty Pharmaceuticals Conference
May 05, 03
15:01 ET	Novavax to Report First Quarter 2003 Financial Results on Wednesday, May 14, 2003
Apr 22, 03
08:32 ET	Novavax, Inc. to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
08:32 ET	Novavax, Inc. to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
Mar 19, 03
08:02 ET	Novavax, Inc. Announces 2002 Fourth Quarter and Year End Results
Mar 13, 03
13:52 ET	Novavax to Report Fourth Quarter and Year End 2002 Financial Results On Wednesday, March 19, 2003
Feb 18, 03
09:03 ET	Novavax, Inc. Completes $16.6 Million Financing
Nov 12, 02
09:10 ET	Novavax, Inc. Announces 2002 Third Quarter Results
08:31 ET	Novavax, Inc.'s New Drug Application for ESTRASORB(TM), a Novel Transdermal, Topical Estrogen Replacement Therapy, Accepted for Review by the FDA
Nov 06, 02
14:28 ET	Novavax to Report Third Quarter 2002 Financial Results on Tuesday, November 12, 2002
Oct 31, 02
08:34 ET	Novavax, Inc. to Present at CIBC World Markets Thirteenth Annual Health Care Conference
Oct 16, 02
14:24 ET	Novavax, Inc. Ranked 100th Fastest Growing Technology Company in North America on the 2002 Deloitte & Touche Technology Fast 500
Oct 04, 02
08:01 ET	Results of Phase III Clinical Trial Reveal Estrasorb(TM) (Estradiol Topical Emulsion) Is Effective in Reducing Vasomotor Symptoms in Post Menopausal Women
Sep 16, 02
16:22 ET	Novavax Comments that E-Selectin Tolerogen Treatment by NIH Prevents Strokes In Animals
Sep 09, 02
19:15 ET	Novavax, Inc. Submits New Drug Application for ESTRASORB(TM), a Novel Transdermal, Topical Estrogen Replacement Therapy
Aug 12, 02
07:31 ET	Novavax, Inc. Announces 2002 Second Quarter Results
Aug 09, 02
08:30 ET	Novavax, Inc. Board Of Directors Adopts Stockholder Rights Plan
Aug 06, 02
10:07 ET	Novavax to Report Second Quarter 2002 Financial Results On Monday, August 12, 2002
Jul 17, 02
08:30 ET	Novavax Announces Co-Promotion Agreement With Ferndale Laboratories, Inc.
Jul 11, 02
08:32 ET	Novavax, Inc. Comments on Recent Hormone Replacement Therapy Study
Jun 27, 02
08:30 ET	Novavax, Inc. Closes $10 Million Convertible Note Financing
Jun 10, 02
10:00 ET	Novavax and IDM Announce Manufacturing Agreement
Jun 05, 02
08:30 ET	Novavax, Inc. to Present at UBS Warburg Global Specialty Pharmaceuticals Conference
May 09, 02
16:33 ET	Novavax, Inc. Announces 2002 First Quarter Results
May 08, 02
08:31 ET	Novavax, Inc. to Present at Deutsche Banc Alex Brown Health Care Conference
May 06, 02
14:14 ET	Novavax to Report First Quarter 2002 Financial Results on Thursday, May 9, 2002
May 01, 02
16:32 ET	Novavax, Inc. to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
Apr 24, 02
18:30 ET	Novavax, Inc. Receives Comments From The FDA
Apr 15, 02
08:30 ET	Novavax, Inc. To Present At Suntrust Robinson Humphrey's 31st Annual Institutional Conference
Apr 12, 02
08:30 ET	Novavax, Inc. Announces Recent Management Appointments
Mar 27, 02
08:30 ET	Novavax, Inc. Initiates Combination Study of ANDROSORB(TM) and ESTRASORB(TM) In Hormone Deficient Women
Mar 22, 02
14:27 ET	Novavax Presents Results of a Phase III Clinical Trial Using ESTRASORB(TM) At Society for Gynecologic Investigation Meeting
Mar 06, 02
08:30 ET	Novavax, Inc. to Present at Salomon Smith Barney 2nd Annual Specialty Pharmaceuticals Conference
Feb 26, 02
08:30 ET	Novavax, Inc. to Present at Lehman Brothers 5th Annual Global Healthcare Conference
Feb 20, 02
16:33 ET	Novavax, Inc. Announces 2001 Fourth Quarter and Year End Financial Results
Feb 19, 02
11:04 ET	Novavax Named to Greater Washington Fast 50
Feb 15, 02
15:13 ET	Novavax to Report Fourth Quarter and Year End 2001 Financial Results On Wednesday, February 20, 2002
Feb 11, 02
07:00 ET	Novavax, Inc. Enters into Long-Term Lease Agreement with Division of Cardinal Health, Inc. for ESTRASORB(TM) Manufacturing Facility
Dec 19, 01
08:01 ET	Novavax Announces NIH Approval of Cooperative Research and Development Agreement (CRADA) for E-selectin Anti-Stroke Therapy
Dec 06, 01
12:00 ET	Novavax Briefs Congressional Panel on Firm's Inactivated Smallpox Vaccine
Nov 05, 01
11:51 ET	Novavax Announces 2001 Third Quarter and Nine Month Financial Results
Sep 05, 01
10:49 ET	FDA Accepts Novavax's New Drug Application for ESTRASORB(TM), a Topical Estrogen Replacement Therapy
Aug 09, 01
05:00 ET	Novavax Announces 2001 Second Quarter and Six Month Financial Results
Jul 10, 01
05:00 ET	Novavax Begins Trading on Nasdaq National Market; Novavax Trading Under New Ticker Symbol NVAX; Novavax Added to Russell 2000 Index
Jul 06, 01
05:00 ET	Novavax Approved for Listing on Nasdaq National Market; Effective July 10, 2001, Novavax to Trade Under New Ticker NVAX
Jul 03, 01
05:00 ET	Novavax to be Included in Russell 3000 Index
Jun 29, 01
14:35 ET	Novavax Expands Licensing Agreement With King Pharmaceuticals For ESTRASORB(TM) and ANDROSORB(TM)
14:35 ET	Novavax Submits New Drug Application for ESTRASORB(TM), A Topical Estrogen Replacement Therapy
May 22, 01
05:00 ET	Novavax to Present at UBS Warburg Global Specialty Pharmaceuticals Conference
May 16, 01
11:56 ET	Novavax to Present ESTRASORB(TM) and ANDROSORB(R) Technologies At The C.E. Unterberg, Towbin Life Sciences Symposium
May 07, 01
05:00 ET	Novavax Announces 2001 First Quarter Financial Results; Company to Highlight Accomplishments at Annual Meeting of Shareholders On May 9, 2001
Mar 13, 01
06:00 ET	Novavax Announces Positive Phase III Trial Results for ESTRASORB(TM)
Mar 12, 01
05:00 ET	Novavax Announces 2000 Fourth Quarter and Year End Financial Results
Feb 26, 01
16:47 ET	Novavax President and CEO Interviewed by CEOCast.com; John A. Spears Discusses Recent Corporate Developments
Jan 08, 01
08:20 ET	Novavax and King Pharmaceuticals Sign U.S. Co-Promotion Agreement for ESTRASORB(TM)
Dec 21, 00
13:08 ET	Novavax Completes Acquisition of Fielding Pharmaceutical
Dec 20, 00
07:58 ET	Novavax Closes $25 Million Convertible Debenture Financing From King Pharmaceuticals, Inc.
Nov 21, 00
12:21 ET	Novavax Appoints John T. Gram as Vice President, Marketing/Business Development
Nov 10, 00
08:00 ET	Novavax Announces 2000 Third Quarter And Nine Month Financial Results
Oct 19, 00
09:52 ET	Novavax Part of Team Awarded NIAID Contract For Malaria Vaccine Production and Support Services
Oct 10, 00
08:00 ET	Novavax Awarded Contract by National Cancer Institute to Manufacture Human Papilloma Virus Vaccine for Efficacy Clinical Trial
Oct 09, 00
09:03 ET	Novavax Appoints Dennis W. Genge as Chief Financial Officer
Oct 05, 00
05:01 ET	Novavax Completes Patient Enrollment of Phase III Trial of ESTRASORB(TM), A Topical Estrogen Replacement Therapy
05:00 ET	Novavax to Acquire Fielding Pharmaceutical for $31.5 Million in Cash and Stock
Oct 03, 00
09:41 ET	Novavax Receives National Cancer Institute Contract To Produce Vaccine For a Clinical Center Clinical Trial
Sep 29, 00
09:10 ET	Novavax Awarded $850,000 Grant From the National Institute of Allergy And Infectious Diseases to Combat Influenza
Sep 14, 00
11:22 ET	Novavax Co-Invented Hepatitis E Vaccine Technology Licensed to SmithKline Beecham
Aug 14, 00
16:00 ET	Novavax Reports Financial Results for the Second Quarter And First Six Months of Fiscal 2000
Aug 10, 00
07:59 ET	Novavax Begins Enrollment into Phase I Clinical Trial of Androsorb(TM), A Testosterone Replacement Therapy for Women
Jun 20, 00
08:03 ET	NOVAVAX to Begin Clinical Trial of ANDROSORB(TM) For Testosterone Replacement Therapy in Women
May 10, 00
07:29 ET	Novavax Announces Financial Results for the First Quarter of Fiscal 2000
May 08, 00
08:00 ET	Novavax and the National Institutes of Health Awarded Key Patents on Hepatitis E Vaccine
May 04, 00
08:00 ET	Novavax Enters Licensing Option Agreement on New Anti-Infectives For the Treatment of Bacterial and Parasitic Infections
May 03, 00
08:03 ET	Novavax Appoints James R. Mirto as Vice President And Chief Operating Officer
Mar 15, 00
08:00 ET	Novavax Receives Over $5 Million From Exercise of Warrants and Stock Options
Mar 13, 00
08:00 ET	Novavax Obtains Two Patents on Antimicrobial Emulsion Technologies - Research Published in Two Peer Reviewed Journals -
Mar 08, 00
09:54 ET	Novavax Announces 1999 Fourth Quarter and Year End Financial Results
Mar 06, 00
10:02 ET	Novavax Receives Important Patent Covering The Production of Viral Vaccines in a Proprietary Cell Line
Feb 02, 00
08:00 ET	Novavax Completes $11 Million Institutional Private Placement
Nov 12, 99
08:00 ET	NOVAVAX Announces 1999 Third Quarter and Nine Month Financial Results
Oct 22, 99
07:31 ET	Novavax Licenses a Series of Novasome(R) Adjuvants to Parkedale Pharmaceuticals for Use With Fluogen(R) Influenza Vaccines
Oct 14, 99
08:02 ET	Novavax Receives National Cancer Institute Contract to Manufacture Vaccines Against Human Papilloma Virus
Sep 14, 99
08:04 ET	Novavax Initiates Multicenter Phase III Trial of ESTRASORB(TM) Hormone Replacement Therapy
Aug 11, 99
12:11 ET	Novavax Announces 1999 Second Quarter and Six Month Financial Results; Company Appoints Denis M. O'Donnell, M.D. Vice Chairman of Board of Directors
07:30 ET	Novavax Acquires Vaccine Development Division of DynCorp
Jun 16, 99
09:30 ET	Novavax Presents Results of ESTRASORB(TM) Phase II Clinical Trial In Symptomatic Post-Menopausal Women
May 17, 99
09:15 ET	Novavax, Inc. Appoints John A. Spears President and CEO
May 14, 99
09:15 ET	Novavax, Inc. Announces First Quarter Results
Apr 22, 99
09:03 ET	Novavax, Inc. Signs Agreement With Cantab for License of Novasome Adjuvants
Apr 16, 99
09:15 ET	Novavax, Inc. Announces Year-End Financial Results
Feb 03, 99
09:02 ET	Second Novavax Spermicide to Begin NIH Sponsored Human Clinical Trials
Jan 28, 99
12:59 ET	Novasome(R) Spermicide Human Clinical Trials Planned
Jan 07, 99
09:01 ET	Novavax, Inc. Announces Research Collaboration with Organogenesis
Nov 17, 98
09:30 ET	Novavax, Inc. Announces Additions to the Board of Directors and the Scientific Advisory Board
Oct 02, 98
11:00 ET	Novavax Repurchases $5.0 Million Series A Custom Convertible Preferred Stock
Sep 26, 98
12:08 ET	Influenza A the Target of New Anti-Microbial Agent by Novavax
12:01 ET	Novavax Anti-Microbial Agent Shown to Destroy Anthrax, Data Presented at ICAAC
Sep 04, 98
09:00 ET	Mitchell J. Kelley Named Interim CEO & President of Novavax
Aug 17, 98
03:17 ET	Novavax Begins Pharmacokinetic Study with ANDROSORB(TM)
Aug 14, 98
09:00 ET	Novavax, Inc. Reports Second Quarter 1998 Results 10 Cents Per Share Loss
Aug 13, 98
10:49 ET	Novavax Completes ESTRASORB(TM) Study
Jul 21, 98
09:00 ET	Novavax Extends Option Agreement with Cantab
Jul 14, 98
09:00 ET	Novavax Begins Pharmacokinetic Study With ESTRASORB(TM)
Jul 01, 98
17:27 ET	Novavax Retains Strategic Communications Firm Russell-Welsh
Jun 01, 98
17:13 ET	Novavax Completes Dosing in Testosterone Trial
May 13, 98
17:08 ET	Novavax, Inc. Reports First Quarter 1998 Results: 11 Cents Per Share Loss
Apr 02, 98
17:09 ET	Wright Named President of New Novavax Biologics Division
Mar 31, 98
17:23 ET	Novavax, Inc. Reports 1997 Results
Mar 25, 98
17:21 ET	Novavax Appoints Vice President of Business Development, a New Post
Mar 24, 98
17:01 ET	Novavax Fills New Post of VP Pharmaceutical Product Development
Mar 18, 98
16:58 ET	Novavax Microbicides Undergoing Testing at University of Michigan Against Biological Warfare Agents
Mar 17, 98
16:56 ET	Novavax Forms Two Operating Divisions
Jan 30, 98
16:53 ET	Novavax Announces $6.5 Million Private Placement
Jan 27, 98
16:50 ET	Novavax Completes Option and Collaborative Agreement with Cantab
Dec 22, 97
16:47 ET	Novavax Technology Delivers Testosterone Topically Without Skin Irritation
Dec 19, 97
08:17 ET	Novavax Technology Eliminates Irritation of Transdermal Estrogen
Dec 18, 97
16:40 ET	Flu Vaccine Response Boosted By Novavax Technology
Nov 12, 97
16:35 ET	Novavax, Inc. Reports Third Quarter 1997 Results
Oct 14, 97
17:46 ET	Novavax, Inc. Announces Four New Patents
Aug 08, 97
17:42 ET	Novavax, Inc. Reports Second Quarter 1997 Results
Jul 31, 97
17:39 ET	Novavax Announces the Appointment of Its New Chief Financial Officer And Treasurer
Jul 22, 97
17:33 ET	Initial Results of Novavax Drug Delivery Trial Termed Statistically Significant
Jun 25, 97
17:28 ET	Novavax's Experimental Menopause Product Reduces Hot Flashes
May 27, 97
17:21 ET	Novavax Receives U.S. Patent for Micellar Nanoparticles For Topical Delivery of Drugs
May 22, 97
17:17 ET	Novavax Receives FDA Permission for Dose-Ranging Clinical Studies of Helicore In Humans Infected with Helicobacter Pylori
May 20, 97
17:13 ET	Novavax CEO Assumes Additional Post of President
Apr 16, 97
17:09 ET	Novavax Receives Third Patent for Helicore(TM) to Kill Helicobacter pylori Bacteria
Apr 14, 97
17:06 ET	Novavax Completes Initial ANDROSORB(TM) Transdermal Testosterone Patient Dosing
Apr 01, 97
17:03 ET	Novavax Receives FDA Permission to Begin Dose-Response Studies With ESTRASORB(TM)
Mar 20, 97
16:59 ET	Novavax Announces Close of $5.1 Million Financing
Mar 18, 97
16:56 ET	Novavax Announces Year End Results of Operations
Mar 04, 97
16:52 ET	Novavax Announces the Appointment of Richard F. Maradie As Its Chief Executive Officer
Feb 10, 97
16:46 ET	Novavax Announces Private Stock Sale